OrganoClick AB (ORGC) AI Stock Analysis

0 Followers

OrganoClick AB

(Nasdaq OMX AB:ORGC)

Select Model

Rating:29Underperform

Price Target:SEK 0.37▼(-16.55% Downside)

Action:reiterated

Date:11/13/26

OrganoClick scores low primarily because of its fragile financial profile: three consecutive years of falling revenue, halved gross margins, persistent losses and a heavily eroded equity base that has required fresh external funding, leaving meaningful dilution risk. Reduced cash burn, lower debt and a near-breakeven free cash flow are encouraging but appear driven by cost and capex discipline rather than business momentum. Technicals offer only modest relief - the stock has bounced above its short- and medium-term averages, yet it sits far below its 200-day average in an established downtrend. With negative earnings and no dividend, valuation provides no support, making this a high-risk turnaround story until sales and margins stabilise.

Positive Factors

Proprietary green-chemistry platformThe company’s proprietary bio-based chemistry addresses multiple material-treatment needs, including water repellency, flame retardancy, and durability. This provides a platform for branded products and industrial solutions while aligning its offering with the structural shift toward less fossil-based and hazardous inputs.

Negative Factors

Revenue contractionMeaningful revenue contraction indicates weaker demand, customer activity, or business mix and reduces the scale available to absorb fixed costs. If the decline persists, it can limit investment capacity, weaken operating leverage, and make a return to profitability more difficult over the next several quarters.

OrganoClick AB (ORGC) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 75.30M
Dividend Yield: ―
Average Volume (3M): 229.61K
Price to Earnings (P/E): -1.7
Beta (1Y): 0.90
Revenue Growth: -27.65%
EPS Growth: 3.02%
Country: Sweden
Employees: 39
Sector: Basic Materials
Sector Strength: 61
Industry: Chemicals - Specialty

OrganoClick AB Business Overview & Revenue Model

Company Description

OrganoClick AB (publ), a technology firm based in Täby, Sweden, was established in 2006. The company specializes in the development, production, and sale of innovative fiber-based materials and chemicals for applications spanning wood treatment, tech...

OrganoClick AB Financial Statement Overview

Summary

Financials are weak across the board. Revenue has declined three years running (SEK 145.9m in 2023 to SEK 79.0m TTM), gross margin has halved to roughly 14-15%, and the company remains loss-making with an operating margin near -32% and net margin close to -38%. The balance sheet is thin: equity eroded from SEK 100.3m in 2021 to SEK 15.2m at end-2025 before being rebuilt to SEK 37.5m via what appears to be a fresh capital raise, leaving ongoing dilution risk alongside SEK 58.8m of debt. The one bright spot is cash flow, where operating cash flow turned slightly positive (SEK 1.3m TTM) and free cash flow narrowed to about -SEK 0.3m on tight cost and capex discipline, but the business is still not self-funding.

Income Statement

12Very Negative

Balance Sheet

22Negative

Cash Flow

36Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	79.04M	106.19M	127.23M	145.87M	115.05M	110.06M
Gross Profit	11.88M	14.86M	31.84M	35.39M	12.94M	18.51M
EBITDA	-8.77M	-12.80M	5.71M	5.95M	-21.19M	-12.92M
Net Income	-30.16M	-36.37M	-17.97M	-15.77M	-41.62M	-31.03M
Balance Sheet
Total Assets	126.08M	135.22M	126.98M	150.75M	162.86M	188.39M
Cash, Cash Equivalents and Short-Term Investments	1.26M	2.68M	538.00K	10.74M	15.20M	34.25M
Total Debt	58.83M	77.78M	51.67M	62.39M	61.68M	53.54M
Total Liabilities	84.76M	114.81M	89.15M	97.34M	95.30M	80.66M
Stockholders Equity	37.47M	15.18M	28.98M	44.58M	58.78M	100.33M
Cash Flow
Free Cash Flow	-306.00K	-10.51M	-5.51M	-8.08M	-35.35M	-52.34M
Operating Cash Flow	1.35M	-8.29M	3.60M	533.00K	-21.22M	-37.69M
Investing Cash Flow	-9.84M	-10.99M	-9.11M	-8.61M	-7.45M	-14.65M
Financing Cash Flow	4.42M	21.42M	-4.69M	3.60M	9.63M	54.56M

OrganoClick AB Technical Analysis

Technical Analysis SentimentPositive

Last Price0.44

Price Trends

50DMA0.32Positive

100DMA0.37Positive

200DMA0.68Negative

Market Momentum

MACD0.04Positive

RSI56.96Neutral

STOCH28.15Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ORGC, the sentiment is Positive. The current price of 0.44 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.32, and below the 200-day MA of 0.68, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 56.96 is Neutral, neither overbought nor oversold. The STOCH value of 28.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ORGC.

OrganoClick AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

SE:ORGC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:PCAT	70Outperform	SEK 19.18M	5.13	―	―	-17.14%	88.76%
SE:HPOL.B	68Neutral	SEK 32.84B	18.12	12.33%	4.41%	-0.82%	-7.46%
Sector *	61Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
SE:AERO	42Neutral	SEK 22.71M	-0.53	-87.92%	―	-11.55%	60.56%
SE:POLYG	41Neutral	SEK 94.24M	-22.30	-1.52%	―	-18.26%	35.77%
SE:NEXAM	40Underperform	SEK 269.56M	-12.35	-9.37%	―	-4.57%	-15.20%
SE:ORGC	29Underperform	SEK 75.30M	-1.70	-156.22%	―	-27.65%	3.02%

* Basic Materials Sector Average

Performance Comparison

SE:ORGC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:ORGC	OrganoClick AB	0.44	-1.27	-74.27%
SE:HPOL.B	Hexpol AB	95.15	19.24	25.34%
SE:NEXAM	Nexam Chemical Holding AB	2.52	-0.49	-16.28%
SE:AERO	Svenska Aerogel Holding AB	0.44	-0.94	-68.12%
SE:POLYG	Polygiene AB	2.66	-5.64	-67.95%
SE:PCAT	Photocat A/S	3.20	-0.60	-15.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026

OrganoClick AB AI Stock Analysis